다발성 경화증 시장 : 다발성 경화증 유형별, 치료법별, 작용기전별, 투여 경로별, 약제 유형별, 최종 사용자별 시장 예측(2026-2032년)

The Multiple Sclerosis Market is projected to grow by USD 58.34 billion at a CAGR of 8.29% by 2032.

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system that affects the brain, spinal cord, and optic nerves. According to the Atlas of MS, approximately 2.8 million people live with MS worldwide, with diagnosis most often occurring in early adulthood and women affected about twice as often as men. These epidemiological realities make MS a high-priority therapeutic area for disease-modifying therapies, relapse management, neuroprotection research, rehabilitation, and long-term care coordination.

For pharmaceutical and biotechnology leaders, the multiple sclerosis market is shaped by the continued expansion of high-efficacy therapies, growing use of biomarkers and MRI monitoring, and increasing pressure to demonstrate durable outcomes in real-world populations. Executive decision-making now depends on integrating clinical efficacy, safety, adherence, patient access, and payer evidence into a unified MS commercialization strategy.

Transformative Shifts in the MS Landscape

The MS treatment landscape has shifted from delayed escalation toward earlier use of higher-efficacy disease-modifying therapies in appropriate patients, supported by evidence that early inflammatory control can reduce relapse activity and MRI lesion accumulation. Monoclonal antibodies, S1P receptor modulators, fumarates, anti-CD20 therapies, and immune reconstitution approaches have expanded treatment choice while increasing the need for individualized risk-benefit assessment.

Another major shift is the growing emphasis on progressive MS, disability accumulation independent of relapse activity, and patient-reported outcomes. Stakeholders are moving beyond annualized relapse rate alone and focusing on confirmed disability progression, cognition, fatigue, mobility, treatment persistence, and quality of life. This transformation is intensifying investment in biomarkers, longitudinal registries, and therapies that address neurodegeneration as well as inflammation.

Cumulative Impact of Artificial Intelligence in MS

Artificial intelligence is increasingly influencing MS research, diagnosis, clinical trial design, and post-market evidence generation. AI-assisted MRI analysis can support lesion detection, lesion volume measurement, brain atrophy assessment, and longitudinal comparison, helping clinicians and researchers manage the high imaging burden associated with MS monitoring. These tools are most valuable when validated against expert neuroradiology workflows and integrated with clinical context.

In drug development, machine learning is being applied to patient stratification, endpoint enrichment, digital biomarkers, and real-world evidence analytics. AI can help identify progression patterns, predict relapse risk, and improve trial efficiency, but its cumulative impact depends on transparent algorithms, diverse datasets, regulatory-grade validation, privacy safeguards, and avoidance of bias across sex, ethnicity, geography, and disability status.

Key Regional Insights Across the MS Market

North America remains a leading MS market due to high diagnosis rates, advanced neurology infrastructure, strong reimbursement pathways, and rapid adoption of specialty therapies, particularly in the United States and Canada. Europe also represents a mature MS environment, supported by national health systems, MS registries, academic neurology networks, health technology assessment processes, and established use of disease-modifying therapies across major economies.

Asia-Pacific is expanding as awareness, MRI availability, specialty neurology access, and healthcare spending rise, although prevalence and diagnosis patterns vary substantially across China, Japan, South Korea, India, Australia, and ASEAN markets. Latin America shows improving access in Brazil, Mexico, and other larger systems, but affordability and uneven specialist coverage remain constraints. The Middle East is strengthening tertiary care and specialty pharmacy channels, particularly in GCC countries, while Africa faces underdiagnosis, limited MRI access, and significant treatment access gaps despite rising recognition of MS across urban centers.

Key Group Insights for MS Stakeholders

Within ASEAN, MS remains comparatively underdiagnosed, but the market is developing as tertiary hospitals, MRI capacity, and neurologist training improve in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries benefit from high healthcare investment and expanding specialty medicine access, creating opportunities for MS centers of excellence, infusion services, and structured patient support programs.

The European Union is central to MS evidence generation, regulatory harmonization, pharmacovigilance, and long-term registry-based research, while BRICS economies combine large patient populations with uneven reimbursement and access maturity across Brazil, Russia, India, China, and South Africa. G7 countries continue to influence global MS treatment standards through clinical trial leadership, payer scrutiny, and adoption of high-efficacy therapies. NATO members overlap significantly with high-income MS markets, where security of pharmaceutical supply chains, data governance, and health system resilience are increasingly relevant to sustained access.

Key Country Insights in Multiple Sclerosis

The United States is the largest commercial opportunity for MS therapies, driven by specialty drug adoption, active clinical trial participation, and broad availability of neurologic subspecialty care, although affordability and payer management remain major market-shaping factors. Canada has among the world's highest reported MS prevalence and strong registry infrastructure, while Mexico and Brazil are expanding access through public and private channels but face budget and regional access disparities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature MS treatment pathways, with Germany often serving as an early-adoption market and the UK emphasizing health technology assessment and evidence-based access. Russia has a sizable MS population but faces procurement and access variability. In Asia-Pacific, China and India offer long-term development potential as diagnosis improves, Japan and South Korea provide advanced specialty care and established neurology networks, and Australia has high MS awareness, strong clinical networks, and structured reimbursement for approved therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence strategies that show durable clinical value beyond relapse reduction, including disability progression, cognition, fatigue, MRI activity, brain volume loss, adherence, and patient-reported outcomes. Market access teams should align early with payers on comparative effectiveness, budget impact, and real-world persistence, particularly as biosimilars and generics intensify pricing pressure in established therapy classes.

Organizations should also strengthen patient support, safety monitoring, and treatment navigation to improve adherence and continuity of care. High-priority opportunities include progressive MS, remyelination, neuroprotection, digital monitoring, biomarker-guided therapy selection, and AI-enabled trial optimization. Partnerships with MS registries, academic centers, imaging networks, and advocacy organizations can improve data quality, support equitable access, and accelerate patient-centered innovation.

Research Methodology

This executive summary is built from a structured review of verified secondary sources, including global MS epidemiology references, regulatory agency communications, peer-reviewed clinical literature, health technology assessment trends, clinical guideline updates, and publicly available information from recognized neurology and MS organizations. The analysis emphasizes data consistency, clinical relevance, and market applicability across therapeutic, diagnostic, regional, and access dimensions.

The methodology combines epidemiological assessment, treatment landscape mapping, regional access evaluation, competitive trend interpretation, and technology impact analysis. Insights were synthesized to support executive decision-making while avoiding unsupported claims, speculative forecasts, market sizing, market share estimates, or unverified market assumptions.

Conclusion

The multiple sclerosis market is moving toward earlier intervention, higher-efficacy treatment, precision monitoring, and broader evidence requirements. While disease-modifying therapies have changed the outlook for many patients, major unmet needs remain in progressive disease, disability prevention, cognitive impairment, fatigue, equitable access, and long-term safety optimization.

For pharmaceutical and biotechnology executives, success will depend on delivering differentiated clinical value, validating outcomes in real-world populations, and building integrated access strategies across mature and emerging MS markets. Organizations that combine scientific innovation with patient-centered evidence and responsible AI adoption will be best positioned to support the next phase of MS care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Multiple Sclerosis Market, by Multiple Sclerosis Type

• 7.1. Primary
• 7.2. Secondary
• 7.3. Relapsing
• 7.4. Progressive-Relapsing

8. Multiple Sclerosis Market, by Treatment Type

• 8.1. Disease-Modifying Therapies
  • 8.1.1. Injectable Therapies
  • 8.1.2. Oral Therapies
  • 8.1.3. Monoclonal Antibodies
• 8.2. Symptomatic Treatments
• 8.3. Acute Relapse Management

9. Multiple Sclerosis Market, by Mechanism of Action

• 9.1. Immunomodulators
• 9.2. Immunosuppressants
• 9.3. Cell Depletion Therapies
• 9.4. S1P Receptor Modulators
• 9.5. Anti-adhesion Molecules

10. Multiple Sclerosis Market, by Route of Administration

• 10.1. Injectable
• 10.2. Oral
• 10.3. Intravenous

11. Multiple Sclerosis Market, by Drug Type

• 11.1. Biologics
• 11.2. Small Molecules

12. Multiple Sclerosis Market, by End User

• 12.1. Hospitals
• 12.2. Specialty Clinics
• 12.3. Homecare Settings

13. Multiple Sclerosis Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Multiple Sclerosis Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Multiple Sclerosis Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Amgen Inc.
• 17.2. AstraZeneca PLC
• 17.3. Bayer AG
• 17.4. Biogen Inc.
• 17.5. Bristol-Myers Squibb Company
• 17.6. Celgene Corporation
• 17.7. F. Hoffmann-La Roche Ltd.
• 17.8. Genentech, Inc.
• 17.9. GlaxoSmithKline plc
• 17.10. Horizon Therapeutics plc
• 17.11. Johnson & Johnson
• 17.12. Merck KGaA
• 17.13. Mitsubishi Tanabe Pharma Corporation
• 17.14. Novartis AG
• 17.15. Otsuka Holdings Co., Ltd.
• 17.16. Pfizer Inc.
• 17.17. Sanofi S.A.
• 17.18. Takeda Pharmaceutical Company Limited
• 17.19. Teva Pharmaceutical Industries Ltd.
• 17.20. TG Therapeutics, Inc.
• 17.21. UCB S.A.
• 17.22. Viela Bio, Inc.